ORIGINAL RESEARCH PAPER
Volume - 10 | Issue - 11 | November - 2021 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

ANALYSIS & RESEARCH OF SARS-COV2 FROM HUMAN BLOOD SERUM FOR CONVALESCENT THERAPY

Clinical Research

Mr. T Md Zimran Abdullah* Biotechnology-Genetic Engineering Student Resident In The Dept. Of Biotechnology SRM IST KTR. *Corresponding Author

Dr. T Anju Associate Prof. Dept. of BIOTECH.

Dr. Prema Associate Prof. SEROLOGIST External Guide

KEYWORDS

COVID, BLOOD SERUM, PLASMA

INTRODUCTION:

India is one of the largest populated countries in the world for many years but has equally succumbed to the impacts of the SARS-Cov2 (COVID-19) pandemic. Research institutes for a brief period of 2 years have been constantly devising a medical cure for the virus. Though in the current scenario vaccination is recommended however the virus can only be handled if the individual contains a high plasma immunity. Hence, The analysis of SARS-Cov2 from the human blood serum is initiated. The plasma therapy for the patient was the earliest and most effective method for the treatment against the (COVID) virus in early 2020, Our study indicates that the plasma of a (COVID) impacted patient can be analyzed and engineered to produce a universal plasma compound that can be used for Convalescent plasma therapy to restore an affected patients immunity and revitalize the antibodies in the concurrent plasma post-infection.

Though vaccination is the recommended treatment against the SARS-Cov2 virus, The viral DNA of the SARS-Cov2 also changes in accordance with the surrounding environment's most impacted form of infection. Once a vaccinated person is affected by the COVID virus the treatment again falls on the immunity levels of the patient which reside in the amount of plasma present in the patient.

The Convalescent test is a serologic test which is an enzyme-linked immunosorbent test (ELISA)-based test to identify SARS-CoV-2 antibodies in serum or plasma components of blood. The ELISA test employments decontaminated SARS-CoV-2 S protein (no live virus) as an antigen. This test is outlined to play down cross-reactivity to antibodies produced to other common coronaviruses that cause less extreme ailments, such as colds.

In any case, potential cross-reactivity cannot be totally ruled out. This serologic test encompasses a specificity of more noteworthy than 99% and an affectability of 96% based on execution assessments. It can be utilized to distinguish past SARS-CoV-2 disease in individuals who were tainted at the slightest 3 weeks. Commercially fabricated counteracting agent tests check for SARS-CoV-2 antibodies in people and are accessible through healthcare suppliers and commercial laboratories.

Also with few treatment alternatives accessible to oversee coronavirus infection 2019 (covid-19), the illness presents a special set of challenges for healthcare suppliers all-inclusive. In expansion to utilizing non-drug intercessions, wellbeing frameworks have formulated procedures to oversee covid-19 utilizing repurposed drugs and returning to more seasoned techniques, such as healing plasma. In the past, gaining strength plasma was utilized as a detached vaccination technique to treat viral maladies, raising expectations that possibly it may be utilized to treat serious intense respiratory disorder coronavirus 2 (SARS-CoV-2), the infection mindful for COVID-19 and a malady with no demonstrated, successful mediations.

Convalescent plasma could be a source of antiviral killing antibodies. Other resistant pathways, such as counteracting agent subordinate cellular cytotoxicity, complement enactment, or phagocytosis are putative components through which gaining strength plasma might apply its helpful impact in patients with COVID-19. Also, anti-inflammatory cytokines, defensins, pentraxins, and other immunomodulatory proteins might have a role in easing systemic provocative reaction disorder, the most pathophysiological premise for acute respiratory trouble disorder and mortality from covid-19 related pneumonia.

Within the pre-vaccine period, gaining strength plasma was utilized to treat viral illnesses such as poliomyelitis, measles, mumps, and more as of late Ebola infection malady, serious intense respiratory disorder coronavirus scourges, with changing degrees of success. Prove proposes that gaining strength plasma collected from survivors of the COVID-19 virus.

Publication of the primary case arrangement from China, numerous observational considers have been distributed, a few on preprint servers, detailing the affiliation between healing plasma and diminished mortality, healing center remain, and viral stack in patients with COVID-19.

As it were two randomized controlled trials on healing plasma utilize in COVID-19 have been distributed, one from China and the other from the Netherlands.

Both were ceased prematurely China ponder since of lacking understanding enrolment, and the Dutch consider since intervals discoveries highlighted the require for an update of the trial. Not one or the other ponder found a mortality advantage.

Convalescent plasma treatment has gotten administrative endorsement for utilizing in patients in a few nations.

This has brought about its broad appropriation in genuine world clinical hone, where it is being utilized to treat patients with a wide range of COVID-19 severity. Given these vulnerabilities, we decided the viability and security of healing plasma in patients with direct COVID-19 conceded to clinics over India to restrain movement to extreme diseases.

Patients aged at least 18 years who had confirmed covid-19 based on a positive reverse transcriptase-polymerase chain reaction (RT-PCR) result for SARS-CoV-2 and had been admitted to the participating hospitals were screened for eligibility.

Consideration criteria were direct sickness with either a halfway weight of oxygen in blood vessel blood/fraction of motivated oxygen (PaO2/FiO2) proportion between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen immersion (SpO2) 93% or less on room air.



PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr



AIMS & OBJECTIVES:

To extract the blood serum of a COVID infected individual and to conduct a plasma analysis to develop a pure plasma compound that is used for Convalescent plasma therapy.

MATERIAL &METHODS:

- POC Plasma analyzer.
- ELISA reader.
- Centrifuge.
- Serum Kit.
- Biosensor.

Study setting:

The following study was conducted at the Department of Biotechnology at HUMA hospital and research institute, Chennai on patients that are infected with the COVID-19 virus presenting to OPD with a decrease in antibodies.

Study design:

The study involving (the PLACID Trial) was an open-label, parallel-arm, stage II, multicentre, randomized controlled trial conducted in 39 tertiary care clinics over India (supplementary figure 1 appears the area of the trial destinations). Of these, 29 were instructing open clinics and 10 were private clinics spread over 14 states and union domains speaking to 25 cities.

Sample Amount Estimation:

To achieve a 90% affirmation level with a 10% marginal error. The minimum required sample amount is calculated to be 60 using E.P.I. infotech.

Sampling technique:

The convalescence sample technique was used to select and study participants from all eligible participants who visited the outpatient department.

Study Period:

This study was carried out during the period of April 2020 to August 2021.

Brief Procedure:

All the patients included in this study were first analyzed for pre & post-COVID +ve symptoms:

1). A detailed clinical analysis of the mode of infection and types of symptoms.

2). Thorough physical & mental examination.

3). Standard Serum kit & ELISA.

4). POC plasma analyzer with BLAST biosensor.

Participants:

Patients matured at slightest 18 a long time who had affirmed covid-19 based on a positive switch transcriptase-polymerase chain response (RT-PCR) result for SARS-CoV-2 and had been conceded to the taking part healing centers were screened for qualification.

Incorporation criteria were direct sickness with either a fractional weight of oxygen in blood vessel blood/fraction of propelled oxygen (PaO2/FiO2) proportion between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen immersion (SpO2) 93% or less on room air,17 and accessibility of a coordinated giver for healing plasma at the point of enrolment.

These criteria were comparable to those for patients with extreme sickness in considers from other nations. We prohibited pregnant and lactating ladies, patients with known touchiness to blood items, beneficiaries of immunoglobulin within the past 30 days, patients with conditions blocking mixture of blood items, members in any other clinical trials, and basically sick patients with PaO.

Randomising & Masking:

An independent biostatistician from the Indian Committee Restorative Research-National Founded of The study of disease transmission, Chennai, India, produced the randomization grouping utilizing the RALLOC module in STATA (College Station, TX). A stratified square randomization methodology was utilized to designate members in a 1:1 proportion to get either convalescent plasma with the leading standard of care (mediation arm) or best standard of care alone (control arm). Stratification was by locales; piece randomization was done with unequal piece sizes. After composed, educated assent had been gotten from qualified patients, the location examiners screened the members for recruitment and reached a part of the central trial planning group to get the randomization grouping, guaranteeing concealment of assignment.

Procedure:

Patients enlisted within the control arm get the best standard of care for covid-19 in keeping with the organization convention, which was directed by the finest accessible prove at the time and rules for the administration of covid-19 issued by wellbeing specialists of the Indian government. The run of treatment conventions taken after by the taking part clinical locales for the administration of patients with covid-19 included antivirals wide range anti-microbial, immunomodulators (steroids, tocilizumab), and strong administration (oxygen through a nasal cannula, confront cover, non-rebreathing confront cover; non-invasive or obtrusive mechanical ventilation; alert pruning). The choice to exchange to the seriously care unit depended on the arrangements of the person trial destinations.

Participants within the intercession arm gotten two measurements of 200 mL of gaining strength plasma, transfused 24 hours apart, in addition to the most excellent standard of care. The primary dosage of healing plasma was transfused at randomization. The two plasma units were collected ideally from diverse givers depending on accessibility and ABO compatibility to extend the chances of accepting gaining strength plasma with killing antibodies.19 On the off chance that two diverse givers were not accessible, both units were collected from a single giver. Gaining strength plasma was collected from patients who had recouped from covid-19 by centrifugal partition utilizing the apheresis gear accessible at the office after getting composed educated assent from the givers. At slightest 20 mL of the given plasma was put away at −80°C for estimation of SARS-CoV-2 killing counteracting agent titers, as solid and endorsed subjective and quantitative tests were not accessible at the beginning of the think about the Commercial subjective Immunoassay.

All participants experienced clinical examination and a run of research facility examinations, counting blood vessel blood gas investigation, total blood check, renal and hepatic work tests, and a coagulation profile on the day of enrolment (day 0) and hence on days 1, 3, 5, 7, and 14. Chest imaging was carried out and biomarkers counting serum ferritin, lactate dehydrogenase, C receptive protein, and D-dimer got on days 0, 3, and 7. Serum for counter-acting agent titer tests was collected on days 0, 3, and 7; these tests were put away at −80°C until advance investigation at the Indian Chamber of Restorative Research-National Established of Virology, Pune, India. RT-PCR for SARS-CoV-2 antibodies from nasopharyngeal swabs was rehashed on days 3 and 7. All members were reached by phone on day 28 to survey their wellbeing status.

A micro-neutralization test for SARS-CoV-2 was performed for deciding the killing counteracting agent titers input away giver gaining strength plasma and member serum from days 0, 3, and 7 at the Biosafety Level-3 office at Indian Board of Restorative Research-

National Established of Virology, Pune taking after institutionalized methods.20 Vero CCL-81 adjusted SARS-CoV-2 (strain NIV2020770) was disconnected at the National Established of Virology, Pune.21 The discovery extend of killing counteracting agent titers was 1:20 to 1:1280. Values detailed as less than 1:20 were considered as imperceptible killing counteracting agent titers; values more prominent than 1:1280 were considered as 1:1280 for investigation. The supplementary record gives full subtle elements.



Observation:

The essential observation of the ponder was a composite of movement to serious illness (PaO2/FiO2 proportion <100 mm Hg) any time inside 28 days of enrolment or all-cause mortality at 28 days. In case movement to serious malady or all-cause mortality can be avoided within the 28 days post-enrolment, the essential result was considered as "good" and in case not it was considered as "poor."

The auxiliary results were time to side effect determination, measured as the extent of members appearing determination of side effects of fever, shortness of breath, or weakness on day 7; alter in oxygen necessity after plasma transfusion, measured as variety in the division of motivated oxygen on days 1, 3, 5, 7, and 14; add up to a term of respiratory bolster amid healing center confirmation, and post-enrolment term of the respiratory back until day 28 or release, whichever was prior; extent of members requiring obtrusive or non-invasive ventilation post-enrollment; consecutive organ disappointment appraisal score over days 0, 3, and 7; transformation to a negative result for SARS-CoV-2 RNA on days 3 and 7; levels of biomarkers post-enrollment, measured as variety in levels over days 0, 3, and 7 in both bunches; and prerequisite of the vasopressor back. Too, we compared clinical enhancement on the World Wellbeing Organization ordinal scale on days 0, 1, 3, 5, 7, 14, and 28 between the two ponder arms.

Statistics:

Expecting that 18% of the mediation arm would meet the composite essential result beneath the invalid speculation and 9% beneath the elective theory, for a control of 80% and importance level of 5%, we calculated that we would require a test estimate of 226 members in each arm, totaling 452 members for the think about. The suspicion that 18% of the members within the control arm would meet the composite essential outcome was based on the finest accessible prove at the time the trial was planned.

The expressive investigation was done by the arrangement of information and introduction of persistent factors as implies and standard deviations or medians and interquartile ranges, as fitting, and categorical factors as proportions. We performed an intention-to-treat investigation after ascribing the lost composite results for movement to serious infection or mortality. For the composite result, we calculated hazard proportions with 95% certainty intervals. A priori, it was chosen to alter for trial locales and any known prognostic covariate that might stay imbalanced between the two arms after randomization. Similarly, we calculated unadjusted and balanced chance proportions for the auxiliary results. The alteration was done for trial locales and nearness of diabetes mellitus. A per convention investigation was performed for auxiliary results. We compared changes in nonstop factors such as oxygen necessity (FiO2), research facility factors (biomarker levels, killing counteracting agent titers) over the period of the hospital.

An altered intention-to-treat investigation was performed on a subgroup of members based on terms of indications at enrolment, location of killing antibodies within the beneficiaries, or the transfused healing plasma. A post hoc subgroup examination compared the composite result between members who gotten healing plasma with perceptible neutralizing antibodies and members within the control arm. We compared members accepting healing plasma with a killing counter-acting agent titer of 1:80 or higher with control members for the essential result. The stratified examination was done for the essential result between intercession and control arms based on stratums such as perceptible killing antibodies at enrolment and terms of side effects at enrolment. To survey the impact of transfusing gaining strength plasma early in COVID-19, we carried out a subgroup examination for the composite result in members who had indications for three days or less at enrolment Interaction was checked.




A.
PCA
Pre– Pandemic Controls
COVID–19
Dim2 (21.9%)
Dim1 (42.3%)
B.
C.
Plasma Recipient
Standard Therapy
A.
Viral load (log RNA copies per swab)
B.
Anti-SARS-CoV-2 S1 IgG (Ratio)
Anti-SARS-CoV-2 S1 IgA (Ratio)
C.
TNF-α
IL-8
IL-17A
Delta
Days







Strengths & Limitations:

The trial (the PLACID Trial) was conducted to create a setting that particularly proves important to all partners, counting policymakers, healthcare suppliers, and patients. To attain this, we welcomed an expression of intrigued from hospitals across India, not fair to a number of centers of brilliance. Healing centers were chosen from both the open and the private divisions, loaning heterogeneity in the foundation and wide social, social, and financial representation of study participants, with a huge extend of comorbidities and displaying highlights. The most excellent standard of care spoken to the care measures likely to be given in a genuine world setting. In spite of the fact that this approach seems to have influenced comparability across think about locales, we accept this loans the trial more generalisability, approximates genuine world scenarios more closely, and within the methodological range of clinical trials, shifts it towards practical trials.

The trial has a few impediments. Since our ponder utilized an open name plan, it was vulnerable to tying down the predisposition of the treating specialists in result ascertainment. This may well be reflected within the higher resolution of subjective side effects such as shortness of breath and weariness famous within the intercession arm. The trial was conducted in 39 healing centers over India, with a few levels of heterogeneity over the trial destinations for the best standard of care and member enrolment. The biomarker measures for ferritin, lactate dehydrogenase, C reactive protein, and D-dimer were conducted utilizing tests from diverse producers. Too, as the widespread was completely different stages over the nation, the numbers selected shifted between destinations, with a plausibility of determination predisposition emerging from clustering of enrolment. We managed with this inclination by factually altering the essential result for trial locales. Moreover, the release criteria for covid-19 were based on Indian government rules and not on the clinic.

Policy:

Utilization of gaining strength plasma as a treatment for COVID-19 is approved for off-label utilization in India. This authorization has been paralleled by flawed hones such as calls for givers on social media and the deal of gaining strength plasma on the dark advertise with over-the-top cost labels in India. Furthermore, in spite of the fact that healing plasma could be a secure frame of treatment when transfused in agreement to the controls fitting for the transfusion of blood and blood items, plasmapheresis, plasma capacity, and estimation of killing antibodies are all asset seriously forms, with a constrained number of organizing in India has the capacity to attempt these methods in a quality guaranteed way.

Result:

Of 1210 patients conceded over 39 trial locales and screened between 22 April and 14 July 2020, 464 qualified patients were enrolled within the study; 235 were randomized to get healing plasma and best standard of care (intercession arm) and 229 were randomized to get the best standard of care as it were (control arm). The essential result at 28 days was not accessible for two patients (one in each arm) who were misplaced to follow-up after release from healing center; nine patients (five in mediation arm, four in control arm) pulled back assent after randomization. Two patients did not get the intercession, healing plasma, after randomization since no coordinate for a giver was accessible.


A.
Pre-Pandemic Controls (n= 16)
Recovered (n= 19) Donors (n= 8) Super-donors (n= 11)
COVID-19 (n= 18) Plasma recipients (n= 9) Standard therapy (n= 9)
Phase I. Baseline analysis: anti-SARS-CoV-2 antibodies, autoantibodies, metabolites, cytokines, and cellular immunity.
Phase II. Longitudinal analysis (0-28 days): viral load, anti-SARS-CoV-2 antibodies, cytokines, and cellular immunity.
B.
r = 0.79 , p = 0.0066
Anti-SARS-CoV-2 S1 IgA (Titers)
PRNT 50 SARS-CoV-2
r = 0.72, p = 0.019
Anti-SARS-CoV-2 S1 IgG (Titers)
PRNT 50 SARS-CoV-2
C.
PCA
Pre-Pandemic Controls
Donors
Super-donors
COVID-19
Dim2 (17.2%)
Dim1 (49.6%)
D.
Cytokine Response in COVID-19
IL-17A
IFN- γ
IFN-α
IL-10
IL-7
G-CSF
IL-6
IL-1β
TNF-α
IL-2
GM-CSF
IL-13
IL-9
IL-12p70
IL-4
IL-5
MCP-1
IL-8
RANTES
IP-10
Pre-Pandemic Controls
Recovered
COVID-19
Log Z-Score
E.
G-CSF Log pg/mL
GM-CSF Log pg/mL
IL-2 Log pg/mL
IL-4 Log pg/mL
IL-7 Log pg/mL
IL-10 Log pg/mL
IP-10 Log pg/mL
IFN-α Log pg/mL
IL-9 Log pg/mL
MCP-1 Log pg/mL
Pre-Pandemic Controls
Recovered
COVID-19



DISCUSSION:

This study found no contrast in 28-day mortality or movement to serious illness among patients with direct COVID-19 treated with healing plasma alongside the best standard of care compared with the best standard of care alone. Furthermore, results did not vary between members getting healing plasma with perceptible killing counteracting agent titers compared with members getting the best standard of care alone; or between those accepting gaining strength plasma with killing counteracting agent titers of 1:80 or higher and those getting the best standard of care alone. Treatment with healing plasma was related to a better resolution of shortness of breath and weariness on day 7. A better extent of members within the mediation arm appeared negative conversion of SARS-CoV-2 RNA on day 7 post-enrolment. The mediation did not, in any case, appear anti-inflammatory properties as we seem not to identify any distinction within the levels of provocative markers such as ferritin & C reactive protein.

The outcomes agree with those of the COVID trial, where 79% of the members had perceptible antibodies at baseline. Be that as it may, the killing counter-acting agent titers in healing plasma in our think about were comparable to those of another ponder, which found that 13-40% patients turned seronegative within the early gaining strength phase. In an arrangement including 175 patients, the analysts recorded that 30% of patients created moo levels of killing antibodies, with titers relating to expanding age and malady severity. We found that members had higher counter-acting agent inspiration and middle-killing counter-acting agent titers than the givers of healing plasma. The contrast in age and seriousness of sickness between members, with givers being more youthful and having milder malady, seems to have driven this distinction. In spite of the fact that all survivors of covid-19 were energized to give plasma, most of the benefactors were youthful and as it was had a mellow illness. Recuperated patients who had direct or serious diseases.

CONCLUSION:

In spite of the fact that the utilize of healing plasma appeared to progress determination of shortness of breath and weariness in patients with direct covid-19 and driven to a higher negative transformation of SARS-CoV-2 RNA on day 7 post-enrollment, this did not interpret into a lessening in 28-day mortality or movement to extreme malady. Ranges of future inquire seem to incorporate viability of healing plasma among killing counteracting agent negative patients and the utilize of healing plasma with tall killing counteracting agent titers. The challenge will be to discover both appropriate patients and appropriate plasma givers. Also, this challenge might restrain the utilize of healing plasma to a little subset of patients.

REFERENCES:

1. Mizumoto K.; Kagaya K.; Zarebski A.; Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019
2. Bendavid E.; Mulaney B.; Sood N.; Shah S.; Ling E.; Bromley-Dulfano R.; Lai C.;

Weissberg Z.; Saavedra R.; Tedrow J.; Tversky D.; Bogan A.; Kupiec T.; Eichner D.; Gupta R.; Ioannidis J.; Bhattacharya J.
3. Jones H.The Importance of diagnostic testing for COVID-19. *Infectious Diseases Hub*; April 2, 2020.
4. yakul, T., Somsap, N., & Rotsatchakul, P. (2012). Study of volatile compounds in Thai rice wine (Sato) produced from wheat. Asia-Pacific Journal of Science and Technology, 17(6), 939-949.
5. Tan R.COVID-19 Diagnostics Explained. *Asian Scientist*; April 8, 2020.
6. Xia J.; Tong J.; Liu M.; Shen Y.; Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *J. Med. Virol.* 2020, 92, 589–594. 10.1002/jmv.25725.
7. American College of Physicians. COVID-19 found in sputum and feces samples after pharyngeal specimens are no longer positive. *Science Daily*; March 30, 2020.
8. Kujawski S. A.; Wong K. K.; Collins J. P.; et al. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nat. Med.* 2020, 10.1038/s41591-020-0877-5.
9. Rutgers University; New Rutgers Saliva Test for Coronavirus Gets FDA Approval: Emergency Use Authorization Granted for New Biomaterial Collection Approach. *Rutgers Today*, April 2020.
10. U.S. Food & Drug Administration. Accelerated emergency use authorization (EUA) summary SARS-CoV-2 ASSAY (Rutgers Clinical Genomics Laboratory). April 10, 2020, pp 1–8.
11. VanGuilder H. D.; Vrana K. E.; Freeman W. M. Twenty-five years of quantitative PCR for gene expression analysis. *BioTechniques* 2008, 44 (5), 619–626. 10.2144/000112776.
12. Wong M. L.; Medrano J. F. Real-time PCR for mRNA quantitation. *BioTechniques* 2005, 39 (1), 75–85. 10.2144/05391RV01.
13. Coronavirus Test Tracker: Commercially Available COVID-19 Diagnostic Tests. *360Dx*, April 21, 2020.
14. COVID-19 test kits are included on the ARTG for legal supply in Australia. Australian Government, Department of Health, Therapeutic Goods Administration, Newsroom, April 21, 2020.
15. Emergency Use Authorization: Emergency Use Authorization (EUA) information, and a list of all current EUAs. U.S. Food & Drug Administration.
16. Find Evaluation Update: SARS-CoV-2 Molecular Diagnostics, COVID-10 Diagnostics Resource Centre; Foundation for Innovative New Diagnostics (FIND).
17. LabCorp launches test for coronavirus disease 2019 (COVID-19). Laboratory Corporation of America, News release. March 5, 2020.
18. Hinton D. M. Emergency use authorization for the 2019-nCoV Real-Time RT-PCR Diagnostic Panel (Centers for Disease Control and Prevention). U.S. Food & Drug Administration, March 15, 2020, pp 1–12.
19. cobas SARS-CoV-2 Test (for the COVID-19 Coronavirus). Roche Diagnostics.
20. GenMark Responds to the SARS-CoV-2 Outbreak. GenMark Diagnostics Inc.
21. TaqPath COVID-19 Multiplex Diagnostic Solution. ThermoFisher Scientific.
22. Notomi T.; Okayama H.; Masubuchi H.; Yonekawa T.; Watanabe K.; Amino N.; Hase T. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 2000, 28 (12), E63–7. 10.1093/var/28.12.e63.
23. Thai H. T. C.; Le M. Q.; Vuong C. D.; Parida M.; Minekawa H.; Notomi T.; Hasebe F.; Morita K. Development and Evaluation of a novel loop-mediated isothermal amplification method for rapid detection of Severe Acute Respiratory Syndrome coronavirus. *J. Clin. Microbiol.* 2004, 42 (5), 1956–1961. 10.1128/JCM.42.5.1956-1961.2004
24. Abbott's Work on COVID-19 Testing. Abbott Laboratories. April 15, 2020.
25. Zhang Y.; Odiwuor N.; Xiong J.; Sun L.; Nayaruaba R. O.; Wei H.; Tanner N.. Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP. *medRxiv* 2020, 2020.02.26.20028373,10.1101/2020.02.26.20028373.
26. Kacian D. L.; Fultz T. J. Kits for nucleic acid sequence amplification methods. U.S. Patent 4888779, 1999.
27. Hologic's Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization. Coronavirus Update, 2020. Hologic, Inc
28. Zhang F.; Abudayyeh O. O.; Gootenberg J. S. A protocol for detection of COVID-19 using CRISPR diagnostics (v.20200321). Broad Institute of MIT and Harvard.
29. Broughton J. P.; et al. CRISPR–Cas12-based detection of SARS-CoV-2. *Nat. Biotechnol.* 2020, 10.1038/s41587-020-0513-4.
30. Serology-based tests for COVID-19. Johns Hopkins Center for Health Security.
31. Wang B.; Potter S. J.; Lin Y.; Cunningham A. L.; Dwyer D. E.; Su Y.; Ma X.; Hou Y.; Saksena N. K. Rapid and sensitive detection of severe acute respiratory syndrome coronavirus by rolling circle amplification. *J. Clin. Microbiol.* 2005, 43 (5), 2339–2344. 10.1128/JCM.43.5.2339-2344.2005.
32. Chen Q.; Li J.; Deng Z.; Xiong W.; Wang Q.; Hu Y. Q. Comprehensive detection and identification of seven animal coronaviruses and human respiratory coronavirus 229E with a microarray hybridization assay. *Intervirology* 2010, 53 (2), 95–104. 10.1159/000264199.
33. Guo X.; Geng P.; Wang Q.; Cao B.; Liu B. Development of a single nucleotide polymorphism DNA microarray for the detection and genotyping of the SARS coronavirus. *J. Microbiol. Biotechnol.* 2014, 24 (10), 1445–1454. 10. 4014/ jmb. 1404. 04024

Review paper reference format:

1. de Souza Luna L. K.; Heiser V.; Regamey N.; Panning M.; Drexler J. F.; Mulangu S.; Poon L.; Baumgarte S.; Haijema B. J.; Kaiser L.; Drosten C. Generic detection of coronaviruses and differentiation at the prototype strain level by reverse-transcription-PCR and nonfluorescent low-density microarray.
2. Hardick J.; Metzgar D.; Risen L.; Myers C.; Balansay M.; Malcom T.; Rothman R.; Gaydos C. Initial performance evaluation of a spotted array Mobile Analysis Platform (MAP) for the detection of influenza A/B, RSV, and MERS coronavirus.
3. Moore S. C.; Penrice-Randal R.; Alruwaili M.; Dong X.; Pullan S. T.; Carter D. P.; Bewley K.; Zhao Q.; Sun Y.; Hartley C.; Zhou E.-M.; Solomon T.; Beadsworth M. B. J.; Cruise J.; Bogaert D.; Crook D. W.; Matthews D. A.; Davidson A. D.; Mahmood Z.; Aljabr W.; Druce J.; Vipond R. T.; Ng L. F. P.; Renia L.; Openshaw P. J. M.; Baillie J. K.; Carroll M. W.; Semple M. G.; Turtle L.; Hiscox J. A. Amplicon based MinION sequencing of SARS-CoV-2 and metagenomics characterization of nasopharyngeal swabs from patients with COVID-19.
4. Comprehensive Workflow for Detecting Coronavirus Using Illumina Benchtop Systems – A Shotgun Metagenomics Sequencing Workflow for Effective Detection and Characterization of Coronavirus Strains. Infectious Disease Surveillance, 2020.
5. Loeffelholz M. J.; Tang Y.-W. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. *Emerging Microbes Infect.*
6. Udugama B.; Kadhiresan P.; Kozlowski H. N.; Malekjahani A.; Osborne M.; Li V. Y. C.; Chen H.; Mubareka S.; Gubbay J. B.; Chan W. C. W. Diagnosing COVID-19: The Disease and Tools for Detection.
7. Zou L.; Ruan F.; Huang M.; Liang L.; Huang H.; Hong Z.; Yu J.; Kang M.; Song Y.; Xia J.; Guo Q.; Song T.; He J.; Yen H.-L.; Peiris M.; Wu J. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.
8. Serology testing for COVID-19. Johns Hopkins Center for Health Security.
9. FDA Fact Sheet: Serological testing for antibodies to SARS-CoV-2 infection. U.S. Food & Drug Administration, April 17, 2020,
10. Hinton D. M. Emergency Use Authorization for qSARS-CoV-2 IgG/IgM Rapid Test (Cellex Inc.). U.S. Food & Drug Administration, April 1, 2020, 1–8.